Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
UPPSALA, Sweden, 12th September, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology.
The Olink platform represents the cutting edge in proteomics technology, delivering exceptional sensitivity and specificity for protein biomarker measurement. Olink Explore HT is the company's latest solution for high-throughput proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2µl of sample. Eurofins Genomics joins a worldwide network of service providers that have adopted the Olink platform. Eurofins Genomics will extend its multi-omic offering to facilitate the discovery and validation of protein biomarkers across biological pathways and sample matrices through the use of the Olink plantform
Jon Heimer, CEO of Olink, stated, “We are immensely pleased to see the Olink Explore platform being utilised by Eurofins Genomics, one of the world’s leading multiomic service providers, that contribute to a safer and healthier world by providing their customers with innovative and high-quality services. With their extensive presence in both the pharma and population health spaces, Eurofins Genomics will apply Olink technology across a broad spectrum of new therapeutic research fields to improve understanding of the development, progression, and outcome of disease.”
Eurofins Genomics will begin applying Olink Explore in three core areas: expanding proteogenomics to enable deeper insight into the basis of disease, increasing biomarker discovery for pre-clinical development and clinical trials, and providing high throughput proteomic analysis for population-scale health studies. Eurofins Genomics is a recognized leader in providing multi-omics services covering genomics, transcriptomics, and epigenomics. Now, with the addition of Olink technology, Eurofins Genomics will offer the most powerful proteomic technology available for a more thorough understanding of the intricate connections between genes, proteins, and diseases.
Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Media contact
Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile:
About
(publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
About Eurofins Genomics
Eurofins Genomics represents the genomic division within the Eurofins Scientific Group. With facilities in Europe, the United States and Asia, Eurofins Genomics is an internationally leading provider of DNA sequencing and genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The European branch is headquartered in Ebersberg, Germany. For further information, please visit
Forward-looking statements
This press release contains express or implied “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995 that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “seek,” “plan,” “outlook,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “currently, “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F for the fiscal year ended December 31, 2022 (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Investor contact Jan Medina, CFA VP Investor Relations & Capital Markets Mobile: +1 617 802 4157 Media contact Michael B. Gonzales, PhD Vice President, Global Marketing Mobile:
